Dr. Mazzola has fifteen years of experience in the biotechnology industry, from fundamental research and technology development to the commercialization of integrated instrumentation platforms. She is President & CEO of Excellin Life Sciences, a company enabling universal engineering of living biological cells. She also founded and chairs NanoBioConvergence, a showcase for nanotechnology innovation in the Life Sciences. Dr. Mazzola was an early employee at Affymax and Affymetrix, developing the high-density array technology that became the revolutionary GeneChip(TM) product line. More recently, she helped reorient business development at Symyx Technologies toward the Life Sciences through collaborations with Merck and Eli Lilly and licensed their first commercial product, winning the Frost & Sullivan 2002 Market Engineering Technology Innovation Award. Dr. Mazzola has been a technology analyst for the California State Senate, Nature Biotechnology, and the National Academy of Sciences. Dr. Mazzola received a B.S. from Kalamazoo College and a M.S. and Ph.D. in Physical Chemistry from Stanford University.
Excellin Life Sciences is revolutionizing biotechnology by enabling novel cell engineering for the pharmaceutical industry. Excellin's technology enables precise optimization of the living cell through direct control of the cellular biochemistry. This process can be applied to millions of cells simultaneously and is gentle enough for primary and stem cells. Excellin’s platform is poised to become an industry standard in the $5.4B biopharmaceutial market with clear paths for expansion into protein-based research and production.
